Clinicopathological Characteristics and Survival Outcomes in Patients with Synchronous Lung Metastases Upon Initial Metastatic Breast Cancer Diagnosis in Han Population

Shaoyan Lin(Nanjing Agricultural University), Binghe Xu(Chinese Academy of Medical Sciences & Peking Union Medical College), Yiqun Li(Chinese Academy of Medical Sciences & Peking Union Medical College), Xiuwen Guan(Chinese Academy of Medical Sciences & Peking Union Medical College), Zijing Wang(Qingdao University), Yimeng Chen(Chinese Academy of Medical Sciences & Peking Union Medical College), Hongnan Mo(Chinese Academy of Medical Sciences & Peking Union Medical College)
Research Square
August 4, 2021
10.21203/rs.3.rs-701307/v1
Cited by 2

Related Papers

Targeted therapeutic options and future perspectives for HER2-positive breast cancer
|Signal Transduction and Targeted Therapy|2019|406
Safety, Activity, and Biomarkers of SHR-1210, an Anti-PD-1 Antibody, for Patients with Advanced Esophageal Carcinoma
|Clinical Cancer Research|2018|218
Safety, anti-tumour activity, and pharmacokinetics of fixed-dose SHR-1210, an anti-PD-1 antibody in advanced solid tumours: a dose-escalation, phase 1 study
|British Journal of Cancer|2018|156
In Real Life, Low-Level HER2 Expression May Be Associated With Better Outcome in HER2-Negative Breast Cancer: A Study of the National Cancer Center, China
|Frontiers in Oncology|2022|119
Molecular landscape and efficacy of HER2-targeted therapy in patients with HER2-mutated metastatic breast cancer
|npj Breast Cancer|2020|74